Plain-English translation of NCT06183489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can treat high-risk smoldering multiple myeloma before the disease advances. Smoldering myeloma is an early stage of multiple myeloma, a blood cancer that affects plasma cells in the bone marrow. Researchers want to understand whether this new medication can slow or stop the disease from progressing in people who haven't yet received other cancer treatments.
People with high-risk smoldering myeloma are at significant risk of developing active multiple myeloma, which causes serious damage to bones and organs. This trial exists to see if treating patients early with this new medication might prevent or delay that progression and improve their long-term outcomes.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive injections of the medication under your skin once every 28 days for 24 cycles (roughly two years). You will visit the research center regularly for these injections and to have blood tests and other monitoring to see how you respond to the treatment. The study team will track whether your disease improves and watch carefully for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Finland
France